Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Elizaveta Efuni ¹, Samuel Cytryn ², Patrick Boland ² and Sabina Sandigursky³, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
Abstract Number: 1366 • 2019 ACR/ARP Annual Meeting
Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
Rebecca Grainger¹, Simon Stebbings ², William Taylor ¹, Andrew Harrison ¹, Celina Capistrano ¹, Niamh Fanning ³ and Lisa Stamp ⁴, ¹University of Otago, Wellington, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: As a tool for self-monitoring and reporting RA disease activity, a smartphone app was developed to enable people with rheumatoid arthritis (RA) to record…
Abstract Number: 1394 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
Leslie Harrold ¹, Joshua Bryson², Thomas Lehman ³, Joe Zhuo ³, Sheng Gao ³, Xue Han ⁴, Amy Schrader ⁵, Sabrina Rebello ⁶ and Joel Kremer ⁷, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Corrona, LLC, Waltham, ⁶Corrona, LLC, Waltham, MA, ⁷Albany Medical College, Albany, NY
Background/Purpose: In the AMPLE trial, patients (pts) with RA with higher baseline anti-CCP2 antibody concentrations showed a better response to treatment with abatacept (ABA) than…
Abstract Number: 1430 • 2019 ACR/ARP Annual Meeting
Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis
Maria de la Vega¹, Generoso Guerra Bautista ², Ricardo Machado Xavier ³, César Pacheco-Tena ⁴, Gastón Solano ⁵, Ronald Pedersen ⁶, Cecila Borlenghi ⁷, Karina Santana ⁸ and Bonnie Vlahos ⁶, ¹CEIM Investigaciones Medicas, Buenos Aires, Argentina, ²Centro de Investigacion Marbella, Panama, Panama, ³Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Pfizer, San Jose, Costa Rica, ⁶Pfizer, Collegeville, ⁷Pfizer, Buenos Aires, Argentina, ⁸Pfizer Inc, Mexico City, Mexico
Background/Purpose: Etanercept (ETN) plus methotrexate (MTX) was shown to be superior to MTX plus another conventional disease-modifying anti-rheumatic drug (DMARD) in an open-label, randomized study…
Abstract Number: 1881 • 2019 ACR/ARP Annual Meeting
Association of Pain Centralization with DMARD Response in Active RA
Andrew Heisler¹, Jing Song ², Dorothy Dunlop ¹, Alyssa Wohlfahrt ³, Marcy Bolster ⁴, Wendy Marder ⁵, Clifton Bingham ⁶, Daniel Clauw ⁷, Tuhina Neogi ⁸ and Yvonne Lee ⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, OH, ³Brigham and Woman's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁸Boston University School of Medicine, Boston, MA, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Despite the availability of potent disease modifying anti-rheumatic drugs (DMARDs), a significant percentage of rheumatoid arthritis (RA) patients do not achieve low disease activity…
Abstract Number: 1981 • 2019 ACR/ARP Annual Meeting
Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki ¹, Shinya Tanaka ², Kojiro Sato ³, Yasuto Araki ¹, Noritsune Kouzu ⁴, Yuho Kadono ², Hiromi Oda ⁵ and Toshihide Mimura ¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, ³Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan, ⁴Medical Kouzu orthopedic and Yachiyo radiation center, Chiba, Japan, ⁵Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Osteoclasts (OCs) are giant multinucleated cells formed from precursors of the monocyte/macrophage lineage and are believe to play a major role in the bone…
Abstract Number: 2101 • 2019 ACR/ARP Annual Meeting
Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Matthew Malus¹, Ly-Elaine Pham ¹, Hrishikesh Samant ¹ and Mamatha Katikaneni ², ¹Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, ²LSUHSC- Shreveport, Shreveport, LA
Background/Purpose: Chronic Hepatitis C virus infection (HCV) has been shown to be associated with connective tissue diseases (CTD). It has been hypothesized that HCV can…
Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Chelsie Fleischer¹, Marie Feser ², Elizabeth Bemis ³, Christopher Striebich ⁴, LauraKay Moss ⁴, Vasilisa Kormendi ⁵, Sharon White ⁵, V. Michael Holers ⁶, Mark Harrison ⁷ and Kevin Deane ², ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, School of Medicine, Aurora, CO USA, Aurora, CO, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷The University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Vancouver, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…
Abstract Number: 2317 • 2019 ACR/ARP Annual Meeting
Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis
Michelle Ormseth¹, Joseph Solus ¹, Annette Oeser ¹ and C. Michael Stein ¹, ¹Vanderbilt University Medical Center, Nashville
Background/Purpose: Patients with rheumatoid arthritis (RA) have accelerated cardiovascular disease independent of traditional risk factors. Previous studies demonstrate that the gut microbiome is altered in…
Abstract Number: 2336 • 2019 ACR/ARP Annual Meeting
Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study
Dionicio Galarza-Delgado ¹, Jose Azpiri-Lopez ¹, Iris Colunga-Pedraza ¹, Rosa Arvizu-Rivera ², Karla Paola Cuellar-Calderon¹, Gisela Garcia-Arellano ³, Ileana Cecilia Reynosa-Silva ¹, Marielva Castro-Gonzalez ¹, Carolina Marlene Martinez-Flores ¹, Raymundo Vera-Pineda ³, Jesus Cardenas-De la Garza ³, Guillermo Elizondo-Riojas ³ and Cinthia Guillen-Gutierrez ⁴, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario " Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ³Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ⁴Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose E. Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with RA have an augmented cardiovascular mortality up to 50% compared to controls. Chronic inflammation of the disease causes endothelial dysfunction and accelerated…
Abstract Number: 2362 • 2019 ACR/ARP Annual Meeting
Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort
Stephanie Saeli¹, Joseph Roots ², Kelly Shields ² and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Data Science, Pittsburgh
Background/Purpose: Lack of adherence to medications is a well-known problem with chronic conditions, RA included. Nonadherence is associated with decreased quality of life and poorer…
Abstract Number: 2388 • 2019 ACR/ARP Annual Meeting
Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort
Beth Wallace¹, Yuqing Gao ², Paul Lin ³, Neil Kamdar ⁴, Jeffrey Curtis ⁵, Kenneth Saag ⁵, Daniel Clauw ⁶ and Akbar Waljee ⁷, ¹Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Institute for Healthcare Policy and Innovation, University of Michigan Medical School, Ann Arbor, MI, ⁴Departments of Obstetrics & Gynecology, Emergency Medicine, Surgery, and Physical Medicine and Rehabilitation, Michigan Medicine, Ann Arbor, MI, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁷Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Prior descriptive work revealed high rates of long term (≥3 months) glucocorticoid (GC) utilization in a commercially insured incident RA cohort [1]. We aim…
Abstract Number: 2767 • 2019 ACR/ARP Annual Meeting
Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed
Kelly O'Neill¹, Cynthia Crowson ², Dana Symons ³, Pamela Sinicrope ⁴, Elena Myasoedova ⁴, Martha Bock ⁴, Jon Tilburt ⁴ and John Davis ⁴, ¹Rheumatoid Patient Foundation, Inc., Winter Springs, FL, ²Mayo Clinic Rochester, Rochester, ³Rheumatoid Patient Foundation, Inc., Rockford, MI, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Treat-to-target is a guiding principle in the management of rheumatoid arthritis (RA), and randomized clinical trials demonstrate its value in improving outcomes. However, implementation…
Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Renuka Nayak¹, Margaret Alexander ¹, Kye Stapleton-Grey ², Carles Ubeda ³, Jose Scher ⁴ and Peter Turnbaugh ¹, ¹UCSF, San Francisco, ²Carnegie Mellon, Pittsburg, ³Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
Abstract Number: 75 • 2018 ACR/ARHP Annual Meeting
Elevated Oxylipin Profile in Autoantibody-Positive Individuals at-Risk of Developing Rheumatoid Arthritis
Vidyanand Anaparti¹, Irene Smolik², Tanja Winter³, Xiaobo Meng⁴, Harold Aukema³ and Hani El-Gabalawy⁴, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Food and Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Preclinical phase of rheumatoid arthritis (RA) is characterized by presence of autoantibodies, including anti-citrullinated protein antibodies (ACPA), years before disease onset. Epidemiological observations suggest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].